Datamonitor: Slow growth in cardiovascular disease will be offset by prospects in diabetes
New Datamonitor research has revealed that pharmaceutical companies will struggle to profit from the cardiovascular disease market over the next decade, despite growing drug usage. Patent expiries and generic competition will have a major impact and Datamonitor expects only AstraZeneca and Novo Nordisk to generate positive sales growth in this sector out to 2018.
(more…)
0 Comments